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We describe the magnitude and kinetics of plasma viremia and nonstructural protein 1 (sNS1) levels in sequential
samples from 167 children with acute dengue, enrolled early in a community study in Vietnam. All children
recovered fully, and only 5 required hospitalization. Among those with dengue virus type 1 (DENV-1), plasma
viremia was signiﬁcantly greater in primary (49) than secondary (44) infections and took longer to resolve. In
primary DENV-2 and 3 infections, viremia was signiﬁcantly lower than among primary DENV-1 infections.
Concentrations of sNS1 were signiﬁcantly higher for DENV-1 than for DENV-2 after adjusting for viremia, with
marked differences in the kinetic proﬁles between primaryand secondary infections. Secondary infection and higher
viremia were independent predictors of more severe thrombocytopenia, and higher viremia was associated with
a smallincreaseinhemoconcentration.Ourﬁndings identify clear serotypeand immune-status related effects onthe
dynamics of dengue viremia and sNS1 responses, together with associations with important clinical parameters.
Dengue is an arboviral disease caused by infection with
1 of 4 related viral serotypes (DENV1–4) [1]. It is a
major threat to global health, with at least 3 billion
persons at risk of infection and 40 million symptom-
atic episodes estimated to occur annually [2]. A wide
spectrum of disease manifestations is seen, ranging from
inapparent infection to severe and potentially fatal dis-
ease [1]. Endothelial dysfunction is the characteristic
feature of severe disease; increased vascular permeability
results in hypovolemic shock, usually accompanied by
deranged hemostasis and signiﬁcant thrombocytopenia.
Neither vaccines nor speciﬁc therapies are currently
available, and management relies on provision of good
supportive care for symptomatic cases.
A variety of viral and host factors are thought to
contribute to pathogenesis [3]. Although severe disease
may occasionally be seen during primary DENV in-
fection, particularly in infants [4, 5], complications are
usually described in association with sequential or sec-
ondary infections [6, 7]. Antibody-dependent enhance-
ment (ADE) is thought to underlie this phenomenon
[8–10], although altered cellular immune responses have
also been implicated [11]. According to the ADE hy-
pothesis, nonneutralizing virion-binding antibodies ac-
quired passively or during an earlier infection bind to the
new virus and facilitate uptake by Fc receptor–bearing
cells, amplifying the infection, and the increased viral
burden drives an immunopathogenic cascade that alters
microvascular function in an undeﬁned way. However,
data on plasma viremia in primary versus secondary
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1292 d JID 2011:203 (1 May) d Duyen et al.infection and in relation to disease severity remain limited and
inconsistent. Early reports indicated that the duration and mag-
nitude of viremia did not vary signiﬁcantly with immune status,
with some studies demonstrating higher viremia in primary in-
fections [12–15]. Subsequent studies showed associations be-
tween increased clinical severity, higher viremia, and secondary
infections among hospitalized Asian children [16, 17]. Other
groups, however, found associations between viremia and clinical
severity without evidence of a rela t i o n s h i pw i t hi m m u n es t a t u s
[18–20]. However, the number of patients with sufﬁcient early
assessments to allow detailed examination of viremia kinetics has
been limited, with the focus primarily on hospitalized patients.
Dengue nonstructural protein 1 (sNS1) is 46 kDa glycopro-
tein secreted by infected mammalian cells, although a biological
role in disease pathogenesis remains unclear [21, 22]. High levels
of circulating sNS1 have been found during acute infections, and
it has been proposed as a prognostic marker for severe disease;
however, there are few data describing the period of the response
or relationships to serotype or immune status [23–25].
The aim of this study was to describe the kinetics of plasma
viremia and sNS1 responses in children with dengue who were
recruited early in the community and monitored carefully
throughout the course of their illness.
MATERIALS AND METHODS
Study Population and Clinical Methods
Recruitment took place at a community clinic in Ho Chi Minh
City run by an experienced dengue physician based at the
Hospital for Tropical Diseases (HTD). Patients aged 5–15 years
who presented with suspected dengue and fever for ,72 h were
eligible for enrollment, provided a parent gave written informed
consent and children aged .12 years gave assent. Ethical ap-
proval was obtained from the Ethical Committee of HTD and
the Oxford Tropical Research Ethics Committee. Patients were
seen daily until afebrile for 2 consecutive days, with standardized
clinical information recorded and a 1-mL venous blood sample
obtained at each visit. The physician was responsible for all
management decisions and could admit to HTD at any time. All
inpatients were assessed daily using the same protocol. Families
were also given a card allowing direct access to the emergency
department at HTD. Patients were invited to attend for review
3–4 weeks from illness onset.
Illness day 1 was deﬁned as the day of reported fever onset.
The day of defervescence was deﬁned as the illness day on which
the oral temperature ﬁrst decreased to <37.5
oC, with no sub-
sequent increase. Fever day was deﬁned in accordance with
earlier publications, taking the day of defervescence as fever day
0 [16, 26]. The following clinical outcomes were summarized
from the daily assessments: the platelet nadir, the presence or
absence of skin and/or mucosal bleeding, and the percentage
increase in hematocrit comparing the maximum value between
days 3–8 of illness with a baseline value taken as the lowest result
obtained on or before illness day 2 or after day 14.
Virological and Serological Assays
Dengue diagnostic capture IgM and IgG enzyme-linked immu-
nosorbent assays (ELISAs) were performed as described else-
where,withuseofpairedenrollmentandconvalescentspecimens
and reagents provided by Venture Technologies [24, 27]. To
deﬁne immune status, an indirect ELISA to pooled recombinant
E proteins of the 4 DENV serotypes (Hawaii Biotech) was used.
In brief, after blocking with 3% Bovine Serum Albumin, 1:50
dilutions of patient or healthy donor plasma samples in phos-
phate-buffered saline were incubated in coated and uncoated
wellsfor2h,followedbyhorseradishperoxidase-conjugatedgoat
anti-human IgG for 2 h, then thesubstrate tetramethylbenzidine,
and the optical density (OD) was read at 450 nm. A cut-off 3
times the mean OD of healthy donor plasma, after subtraction of
the OD in uncoated wells, was used; a sample to cut-off ratio
,0.8 was considered to be negative, and a ratio .1.2 was con-
sidered to be positive.A negativeindirect ELISA resultinthe ﬁrst
72 h with no increase in dengue-reactive IgG by day 7 deﬁned
a primary infection, and a positive indirect ELISA result within
72 h and/or an equivocal response, with a clear increase in
dengue-reactive IgG greater than the IgM response by day 7,
deﬁned a secondary infection.
DENV detection by reverse-transcription polymerase chain
reaction (RT-PCR) in enrollment plasma samples was per-
formed using the method described by Shu et al [28]. Sub-
sequently, daily DENV load was measured using an internally
controlled, serotype-speciﬁc, real-time RT-PCR assay, as de-
scribed elsewhere [29]. The assay is equally sensitive for DENV-
1, -2, and -3, as demonstrated by the equivalent detection of
standardized amounts of in vitro transcribed RNA molecules
that correspond to the respective target sequence in each sero-
type. Serial plasma samples from each patient were assayed on
the same day and grouped by serotype, and all assays were done
by one person blinded to the clinical outcome. The day of viral
clearance was deﬁned as the illness day on which the RT-PCR
ﬁrst became negative and remained negative.
Qualitative sNS1 assays were performed using Biorad Platelia
Dengue NS1 Antigen kits, according to the manufacturer’s in-
structions. A quantitative assay was developed using the same
kits and using afﬁnity-puriﬁed recombinant baculovirus derived
DENV-2 sNS1 to establish standard curves, with serial dilutions
of sNS1 from 2 ng/mL to 0.0625 ng/mL, run in duplicate on
each plate. All serial samples, diluted up to 1:10,000, from any
patient positive on the qualitative sNS1 assay were run on the
same plate; the limit of detection was 0.125 ng/mL.
Statistical Methods
For viremia and sNS1 concentrations, the illness day 3 value, the
proportion of patients with undetectable measurements at ill-
ness day 6, and the area under the curve (AUC) of the serial
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trapezoidal rule) were used as summary measures describing the
period when almost all patients were observed. In additional
sensitivity analyses, we examined viremia and sNS1 concen-
trations on fever day -2, the proportion of patients with un-
detectablemeasurementsonfeverday0,andforviremiaonly,the
maximum observed value and time to viral clearance (patients
without documented clearance were treated as censored on the
last day of assessment). Finally, when possible, we determined the
peak viral load (ie, if there were documented lower viral loads on
t h ed a y sb e f o r ea n da f t e rt h em a x i m u mo b s e r v e dv a l u e ) .
To compare viremia kinetics, we predeﬁned the following
contrasts to be of primary importance: pair-wise comparisons
of serotypes in the subgroups of patients with primary and
secondary infection and comparisons of primary versus sec-
ondary infection within dengue serotypes. Comparisons of
log-transformed viral load measurements were based on linear
regression models, comparisons of detectable rates on a Bayesian
version of logistic regression [30], and comparisons of time to
viral clearance on a Cox regression model. In all cases, we
included dummy covariates for each serotype immune status
combination and tested for signiﬁcance of the prespeciﬁed
contrasts. We corrected for multiple comparisons with use of
a single-step approach based on the joint asymptotic multivar-
iate distribution of the contrasts [31]. Plasma sNS1 kinetics were
analyzedsimilarly,exceptthat we excludedpatientsinfectedwith
DENV-3 because of the limited available data.
Clinical outcomes were modeled with linear or logistic re-
gression models, as appropriate. The following covariates were
jointly included in the models: log10 dengue viremia on illness
day 3, serotype, and immune status. For laboratory outcomes,
we also added the baseline value of the respective parameter as
a covariate. Alternative models that replaced log10 dengue vi-
remia with log10 sNS1 were also examined. Finally, we tested for
aninteractionbetweenimmunestatusandserotype andaddedit
to the model if signiﬁcant.
A small number of children were not followed up until illness
day 6, and we used a single random imputation for missing viral
load and sNS1 values from these patients. All analyses were
performed using R, version 2.9.1 [32], and the R packages
multcomp, arm, and mice.
RESULTS
Characteristics of the Study Population
FromJune2006throughMarch2008,301childrenwereenrolled
in the study; 203 (67%) had dengue conﬁrmed by RT-PCR, and
8 (3%) had serological evidence of infection. All dengue diag-
nostics were negative in 80 children (27%), and the results were
indeterminate for 10 (3%). For the present study, we included
167 (82%) of the RT-PCR–positive patients; children were ex-
cluded because they had unknown or mixed (n 5 6) or DENV-4
(n 5 2) infections, they entered the cohort late (n 5 9), or their
immune status was indeterminate (n 5 19). Each child attended
a median of 6 daily visits (interquartile range [IQR], 5–6 daily
visits) during the acute illness, 11 (7%) of 167 stopped review
before day 6 (but all were afebrileat this time), and 8 had already
cleared their viremia. One hundred ﬁfty-three (92%) of 167
attended the follow-up visit. Daily plasma viral load measure-
ments were performed for all participants, and daily sNS1 con-
centrations were measured for all participants enrolled from
June 2006 through September 2007 (82 [49%] of 167).
The main demographic and clinical characteristics of the
study population are summarized in Table 1. The median age of
the children was 11 years (IQR, 9–13 years), and 83 (50%) were
female. DENV-1 was the predominant serotype identiﬁed; 93
(56%) of the children were infected with DENV-1, 36 (22%)
with DENV-2, and 38 (23%) with DENV-3. The proportion
with primary infections was lower for DENV-2 than for the
other serotypes (P 5 .04, by v
2 test): 53% for DENV-1, 28% for
DENV-2, and 45% for DENV-3. Time to defervescence was
generally shorter for secondary than for primary infections (Cox
regression hazard ratio, 1.46; 95% conﬁdence interval [CI],
1.06–2.02; P 5 .02), with no evidence of a serotype effect
(P 5 .15, likelihood ratio test). Almost all children (155 [93%]
of 167) received some intravenous ﬂuid replacement as out-
patients, primarily maintenance infusions given during the early
febrile phase; a similar pattern of ﬂuid intervention was seen
among children without dengue, with 73 (91%) of 80 receiving
infusions. Two children were reviewed in the emergency de-
partment but not admitted, and 5 children required hos-
pitalization. Two of the hospitalized children developed dengue
shock syndrome but recovered promptly after standard ﬂuid
resuscitation; both had secondary infections (DENV-2 and
DENV-3), and the remaining 3 hospitalized children included 2
primary infections and 1 secondary infection (all DENV-1).
Plasma Viremia Kinetics
Key summaries of plasma viremia and sNS1 concentrations are
presentedin Table2,with thekinetics ofthese parameters shown
in Figures 1 and 2. Additional summary information in relation
to fever day, plus data on time to viral clearance and maximum
viral load, are displayed in Supplementary Table 1 and Supple-
mentary Figure 1. AUCs and illness day 3 measurements cor-
related strongly with each other (partial correlation after
controllingfor immune status andserotype,0.96for viremia and
0.98 for sNS1 concentration). There was also a statistically sig-
niﬁcant association between the viremia and sNS1 measure-
ments (partial correlation, 0.58 for AUCs and 0.56 for day 3
measurements; both P , .001).
Patients with DENV-1 primary infections had signiﬁcantly
higher viral loads, expressed in terms of illness day 3 measure-
ments and AUCs, compared with patients with secondary DENV-
1i n f e c t i o n s( b o t hP , 0.02). Maximum observed viral loads were
1294 d JID 2011:203 (1 May) d Duyen et al.almost 1 log10 copies/mL higher for primary compared with
secondary DENV-1 infections (median viral load, 8.78 vs 7.83
log10 copies/mL, comparison adjusted for enrollment day;
P 5 .006). Peak viremia could be identiﬁedin 17primary and20
secondary DENV-1 infections, and median peak values in the 2
groups were 9.37 and 8.42 log10 copies/mL, respectively. More-
over, patients with primary DENV-1 infection were viremic for
signiﬁcantly longer than were patients with secondary DENV-1
infections (median, 7 vs 5 days to viral clearance; P , .001) and
were more likely to still be viremic at defervescence (31% vs 66%
below the limit of detection on fever day 0; P 5 .01). In relation
to fever day, we found very similar primary and secondary
plasma viral loads on fever day -2. Results for comparisons on
earlier fever days -3 and -4 (data not shown) suggest higher viral
loads in the primary group, but the number of observations
available at these times was small.
Comparisons between serotypes revealed that viral loads in
primary infections were signiﬁcantly lower for DENV-2 and
DENV-3 (P , .01, for each serotype comparison with DENV-1,
both for illness day 3 and AUCs), with the median day 3 viremia
measurements 2.5 and 1.6 log10 copies/mL lower for these
serotypes than for DENV-1. The results suggest that higher
plasma viral load occurs in patients with secondary DENV-2
infection and, possibly, DENV-3 infection, compared with pri-
mary infection; however, the number of infections due to these
serotypes was small, and no statistically signiﬁcant differences
were observed for any of the predeﬁned analyses. Viremia was
undetectable in the majority of patients with these serotypes by
illness day 6, with no differences in the proportion of patients
with primary or secondary infections testing negative at this
time or on the day of defervescence.
Plasma sNS1 Kinetics
The magnitude and kinetics of the sNS1 responses also varied
markedlyby serotype and immune-status. Patients with primary
DENV-1 infection had high plasma concentrations from the
early febrile period persisting at high levels throughout the
illness, and in secondary DENV-1 infections the plasma
levels decreased rapidly from day 4–5 onward. Plasma sNS1
levels on illness day 3 were markedly lower in patients with
DENV-2 infection, compared with patients with DENV-1 in-
fection (P < .001, for comparisons in both primary and















Age, years 11 12 10 12 10 12
Median (IQR) (8-13) (9-13) (6-11) (11-14) (7-13) (10-13)
Sex, female
n (%) 25 (51%) 15 (34%) 6 (60%) 15 (58%) 11 (65%) 11 (52%)
Day of illness at enrolment
Day 1, n (%) 12 (24%) 8 (18%) 4 (40%) 2 (8%) 3 (18%) 2 (10%)
Day 2, n (%) 21 (43%) 19 (43%) 5 (50%) 15 (58%) 12 (71%) 7 (33%)
Day 3, n (%) 16 (33%) 17 (39%) 1 (10%) 9 (35%) 2 (12%) 12 (57%)
Days of sequential follow-up
Median (IQR) 6 (5-7) 6 (5-6) 6 (5-6) 5 (5-6) 6 (5-6) 6 (4-6)
Attended convalescent review
n (%) 46 (94%) 37 (84%) 10 (100%) 26 (100%) 15 (88%) 19 (90%)
Clinical outcomes













Day of illness of platelet nadir
Median (IQR) 6 (5-7) 5 (5-6) 5 (4-7) 5 (4-6) 6 (4-6) 5 (5-6)
Bleeding
Skin only, n (%) 29 (59%) 24 (55%) 7 (70%) 13 (50%) 12 (71%) 12 (57%)
Mucosal, n (%) 4 (8%) 3 (7%) 0 (0%) 3 (12%) 0 (0%) 1 (5%)
Percentage hemoconcentration
Median (IQR) 14 (7-22) 11 (6-19) 10 (6-14) 16 (12-26) 8 (3-12) 14 (5-19)
Day of defervescence
Median (IQR) 6 (5-6) 5 (5-6) 5 (4-6) 5 (4-5) 6 (5-6) 5 (5-6)
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adjustment for log10 viral load on the same day (both P ,
.006). One third of all DENV-2–infected patients were consis-
tently sNS1 negative throughout the illness course; although 7 of
9 had secondary infections, the remaining 2 had primary in-
fections. Patients with secondary DENV-1 and DENV-2 in-
fections were signiﬁcantly more likely to have undetectable sNS1
levels by illness day 6. compared with patients with primary
infections due to the same serotype (both P < .02). Data were
available for only 6 patients with DENV-3 infection, but the
resultssuggest a patternsimilar tothat forpatientswithDENV-1
infection.
Associations with Clinical Outcomes
Data describingthe main clinicaloutcomes are presented inTable
1. Median platelet counts were consistently lower in secondary
infections during illness days 3–7 for all 3 serotypes (Figure 3).
Linear regression models showed that secondary infection (esti-
mate, -32,680 cells/lL; 95% CI, -45,796 to -19,564; P , .001) and
higher viral load on illness day 3 (estimate, -11,696 cells/lLp e r
11log10 copies/mL; 95% CI, 215,373 to 28019; P , .001) are
independentpredictorsofalowerplateletnadir,withnoevidence
that serotype plays a role (F test, P 5 .53) or of an interaction
between immune status and viremia (F test, P5 .24). In addition,
higher plasma sNS1 concentrations were signiﬁcantly associated
with a lower platelet nadir after adjusting for serotype and im-
mune status (P , .001), but the association was only borderline
signiﬁcant when entered jointly with viremia (P 5 .07). Minor
clinical bleeding was noted in 61%–71% of the patient subgroups
(Table 1), but no association with serotype or immune status was
apparent.
The severity of vascular leakage was assessed in terms of
maximum percentage hemoconcentration. In the regression
model, a signiﬁcant interaction between serotype and immune
status was apparent (F test, P 5 .03); thus, greater hemo-
concentration was observed in secondary than in primary in-
fections due to DENV-2 (P 5 .06) and DENV-3 (P 5 .01) but
not DENV-1 infections (P 5 .65). In fact, among the patients
with DENV-1 infection, a greater proportion of those with
primary (16 [33%] of 49) than with secondary infections (11
[25%] of 44) developed hemoconcentration >20% relative to
baseline. The severity of hemoconcentration in patients with
primary DENV-3 infection was also signiﬁcantly less than that
seen in primary DENV-1 infection (P 5 .008). Results obtained
after adjustment for the cumulative ﬂuid volume perkilogram
body weight were very similar, with no evidence for any effect of
immune status for DENV-1 infection. Finally, higher viral load
on illness day 3 was an independent predictor of higher
Table 2. Summary and Comparison of Plasma Viremia Levels and sNS1 Concentrations Between Illness Days 3–6 by Dengue Serotype
and Immune Status
DENV-1 DENV-2 DENV-3
Primary Secondary Primary Secondary Primary Secondary
Dengue viremia
Number of observations 49 44 10 26 17 21
Day 3 measurement
a 8.34 7.71 5.85 7.54 6.77 7.62
Median (IQR) [log10-copies/ml] (7.56–8.96) (6.17–8.41) (4.43–7.55) (6.23–8.26) (5.80–7.56) (6.15–7.97)
AUC days 3-6
b 8.07 7.48 5.76 7.32 6.63 7.45
Median (IQR) [log10-copies/ml] (7.35–8.89) (6.16–8.28) (4.69–7.35) (6.40–8.03) (5.50–7.51) (6.14–8.17)
Day 6 measurement
c 20 (41%) 40 (91%) 9 (90%) 24 (92%) 13 (76%) 16 (76%)
n (%) below the detection limit
sNS1 Plasma concentration
Number of observations 26 23 9 18 5 1
Day 3 measurement
d 2,569 390 4 10 4,443 9,408
Median (IQR) [ng/ml] (1,639 - 4,734) (85 - 1,722) (2 - 5) (ND - 101) (2,804 - 4,990) (-,-)
AUC days 3–6
e 9,310 225 11 8 14,654 13,751
Median (IQR) [ng/ml] (4,478 - 15,219) (43 - 2,699) (4 - 14) (ND - 163) (7,18 - 15,051) (-,-)
Day 6 measurement
f 0 (0%) 20 (90%) 3 (33%) 16 (89%) 0 (0%) 1 (100%)
n (%) below the detection limit
NOTE. ND indicates below the detection limit for the assay. P values adjusted for multiple comparisons (D1.P5DENV-1, primary infection etc.; only DENV-1 and
DENV-2 are included in comparisons of sNS1 in plasma):
a Plasma viremia – day 3: D1.P – D2.P (P , .001), D1.P – D3.P (P 5 .008), D1.P – D1.S (P 5 .01), all other adjusted P . .4
b Plasma viremia – AUC: D1.P – D2.P (P , .001), D1.P – D3.P (P 5 .004), D1.P – D1.S (P 5 .02), all other adjusted P . .35
c Plasma viremia – detectable on day 6: D1.P – D2.P (P 5 .13), D1.P – D3.P (P 5 .18), D1.P – D1.S (P , .001), all other adjusted P . .5
d sNS1 in plasma – day 3: D1.P – D2.P (P , .001), D1.S – D2.S (P 5 .001), D1.P – D1.S (P 5 .02), D2.P – D2.S (P 5 1.00)
e sNS1 in plasma – AUC: D1.P – D2.P (P , .001), D1.S – D2.S (P 5 .002), D1.P – D1.S (P , .001), D2.P – D2.S (P 5 .94)
f sNS1 in plasma – detectable on day 6: D1.P – D2.P (P 5 .10), D1.S – D2.S (P 5 1.00), D1.P – D1.S (P , .001), D2.P – D2.S (P 5 .02)
1296 d JID 2011:203 (1 May) d Duyen et al.hemoconcentration, although the effect size was small (estimate,
11.2% per 11log10 copies/mL; 95% CI, .15–2.26; P 5 .03), and
no association was observed between hemoconcentration and
sNS1 level (P 5 .23).
DISCUSSION
Inthisprospectiveobservationalstudy,wedescribethemagnitude
and kinetics of plasma viremia and sNS1 levels in 167 children
enrolled in a community dengue study. Early recruitment facil-
itated viral identiﬁcation in virtually all cases, and careful follow-
up allowed detailed assessment of the responses over time.
In the 93 children infected with DENV-1, plasma viremia,
assessed by a variety of methods, was signiﬁcantly greater in
primary than in secondary infections and took longer to resolve.
By contrast, the measurable burden in primary DENV-2 and
DENV-3 infections was signiﬁcantly lower than that in primary
DENV-1 infection, with a suggestion of increased viral load at
least during secondary DENV-2 infection. All comparisons were
predeﬁned and adjusted for multiple testing, and thus, the re-
sults are quite conservative.
The characteristics of the sNS1 responses also differed
markedlyacross the groups.We found considerablyhigher sNS1
concentrations in DENV-1 infection than in DENV-2 infection,
even after adjusting for viremia. Although the sNS1 kits used are
reported to bind all serotypes similarly, the possibility of dif-
ferential sensitivity for DENV-1 and DENV-2 cannot be ex-
cluded. However, although all viruses identiﬁed during this
period were from the same lineage [33], there was no meas-
ureable sNS1 response in one-third of DENV-2–infected pa-
tients, including 2 with primary infections, indicating that, in
DENV-2,thereisalsoconsiderablevariabilityinsNS1responses.
We also noted a rapid decrease in secondary but not primary
infections from day 5 of illness, potentially consistent with im-
mune complex formation. Most patients had mild disease and
were treated in the community without development of com-
plications, emphasizing the bias that may be introduced by fo-
cusing research on hospitalized patients. Although previous
studies have suggested a relationship between sNS1 levels and
disease severity, formal prospective evaluation across a range of
health care settings should be performed to assess whether
quantitative sNS1 measurements are actually useful for risk
prediction.
Figure 1. Dengue viremia kinetics in 167 children with dengue, by serotype and immune status, presented according to illness day. Gray lines
correspond to individual children, and the thick lines correspond to loess scatter plot smoothers.
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ﬁndings with respect to immune enhancement. First, the results
reﬂect concentrations detectable in plasma, but virus and/or
protein might be sequestered in other tissues or be inaccessible
in immune complexes and still retain the potential to inﬂuence
disease pathogenesis. Second, despite a study design aimed at
early recruitment, of necessity, we could only observe the re-
sponses after the onset of symptoms. In the presymptomatic
phase of secondary infection, ADE may transiently boost in-
fection, prompting a robust anamnestic immune response, such
that the plasma viral load may already be decreasing by the time
the patient becomes symptomatic. In primary infection, peak
viremia may occur later, with the whole viremia-to-time curve
shifted to the right. Leaving aside ADE, the study reveals that
DENV-1 behaves differently from other serotypes, suggesting an
intrinsic ﬁtness advantage that allows development of high viral
loads in the absence of pre-existing antibody, in contrast to
DENV-2 and DENV-3, in which a heterologous immune re-
sponse seems necessary to develop high viral loads. However,
RT-PCR measures genome copies, comprising both infectious
and noninfectious viral particles, and the relative proportions
may well vary between serotypes. Assessment of virus titers
based on plaque assay methods should clarify whether DENV-1
is indeed associated with a higher infectious viral burden than
other serotypes. Finally, although these results reﬂect the re-
sponses of the serotypes and genotypes circulating in Vietnam
during the study period, further work is needed to determine
whether the ﬁndings are generalizable to other settings. If con-
ﬁrmed, the implications for studies of transmission dynamics in
different immune landscapes may be considerable.
With respect to clinical outcome, examination of relation-
ships to individual markers of severity indicates that secondary
infection and higher viral load were independent predictors of
more severe thrombocytopenia. Higher viral load was also in-
dependently associated with a small effect on hemoconcentra-
tion; consistent with this ﬁnding, hemoconcentration of .20%
was more frequent in primary than in secondary DENV-1 in-
fections. Previously, in a study of secondary DENV-3 infections,
Libraty et al [17] reported associations between higher viral load
and bothhemoconcentration andthrombocytopenia; thisstudy
provides evidence that higher viral load also exerts an effect in
primary infection and across different serotypes.
Figure 2. Plasma sNS1 concentration kinetics in 82 children with dengue, by serotype and immune status, presented according to illness day. Gray
lines correspond to individual children, and the thick lines correspond to loess scatter plot smoothers. (Only one child with secondary DENV-3 was
assessed.)
1298 d JID 2011:203 (1 May) d Duyen et al.In conclusion, we found that the infecting serotype and the
host’s primary or secondary immune status contribute to vire-
mia and sNS1 proﬁles during dengue infection and inﬂuence
various important clinical parameters. Many other host and
viral determinants probably contribute, and because of the in-
trinsic variability in such biological factors, it is likely that future
studieswill require early enrollment of large numbers of patients
if the relative contributions to pathogenesis are to be clearly
elucidated. Such knowledge of relationships between viremia,
viral biomarker kinetics, and clinical outcome will be invaluable
for the design and conduct of therapeutic trials aimed at pre-
venting and/or treating severe dengue and should also improve
our understanding of pathogenesis and transmission dynamics.
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